Avantor price to free cash flow AVTR
Market value divided by free cash flow over the last twelve months, since 2020.
- Today, Nov 2, 2026
- 23.2×
- 7-year median
- 20.7×
- Against its 7-year history
- 70th
- percentile: 0 is its lowest day, 100 its highest
- 7-year range
- 10.2× to 29.6×
- Peer median
- 25.6×
Avantor's price to free cash flow is 23.2× as of Nov 2, 2026.
That is above its 7-year median of 20.7×, higher than on 70% of days in the last 7 years.
Over that time it ranged from 10.2× in Mar 2026 to 29.6× in Dec 2021.
The median for 10 diagnostics and research stocks of a similar size is 25.6×.
Price to free cash flow over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 23.2× | 10.2× | 25.7× |
| 2025 | 14.9× | 12.3× | 20.3× |
| 2024 | 19.5× | 18.9× | 26.6× |
| 2023 | 22.2× | 16.9× | 23.8× |
| 2022 | 17.8× | 16.2× | 26.5× |
| 2021 | 29.6× | 18.3× | 29.6× |
| 2020 | 24.8× | 20.1× | 24.9× |
Against its peers
Companies in Medical - Diagnostics & Research nearest Avantor's size, closest first, today.
| Company | Price to free cash flow |
|---|---|
| AVTRAvantor | 23.2× |
| BIOBio-Rad Laboratories | 27.7× |
| CAICaris Life Sciences | 73.2× |
| RVTYRevvity | 30.3× |
| LNTHLantheus | 16.9× |
| MEDPMedpace | 25.6× |
| BLLNBillionToOne | 157× |
| CDNACareDx | n/m |
| DGXQuest Diagnostics | 20.0× |
| VCYTVeracyte | 23.7× |
| LHLabcorp | 25.0× |
| Peer median | 25.6× |
What the price to free cash flow tells you
Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.
Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.
More on Avantor
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.